Edmond de Rothschild Investment Partners (Paris) and UFG PE (Paris), current investors in the company, have also subscribed to the current round of financing. Aelios Finance served as financial advisor to Biospace med.
The company said that infusion of new capital from these venture funds will allow the worldwide market expansion of EOS ultra low dose 2D|3D Xray.
The company says EOS, which is based upon a patented particle detector technology, captures a whole or partial body image in a single scan without the need for any digital stitching and at a reduced dose. In addition, the system allows simultaneous bi-plane image acquisition (frontal and lateral).
Marie Meynadier, president and CEO of Biospace med, said: “This new round of financing will accelerate the worldwide commercial deployment of EOS, which is already installed in several European countries and Canada. With the recent FDA approval to market EOS in the US, this financing package will accelerate our market penetration there as well.”